An HIV seroincidence study was conducted to identify a high-risk population
for HIV prevention trials. Inclusion criteria were male gender, homosexual
behavior, age between 18 and 50 years, and negative HIV serostatus; 862 st
udy subjects were screened and 753 were enrolled and observed during follow
-up for a mean of`1.5 years. In this population, 34 people had HIV seroconv
ersions for an overall annual seroincidence of 3.1% (95% confidence interva
l [CI], 2.18-4.1%). Among study subjects <20 years old, annual incidence wa
s 8.4% (95% CI, 1.7%-15%). Independent risk factors for seroconversion were
age <25 years (p = .01), hepatitis B core antibody seropositivity (p > .01
), sex at first encounter in the preceding 6 months (p = .11), and a histor
y of gonorrhea or condyloma in the 6 months before seroconversion (p = .04
and p = .08, respectively). Al enrollment, 85% of the eventual seroconverte
rs said they would participate in a vaccine trial; all agreed to participat
e when told there would be a placebo arm. Follow-up rates were 97%, 91%, an
d 88% at 6, 12, and 18 months, respectively. The HIV-1 subtype was B for ea
ch of the first 17 seroconverters. These data demonstrate the suitability o
f this cohort for HIV prevention trials, based on high HPV incidence and re
tention rates, and a willingness to participate in such trials.